Skip to main
ANGO

AngioDynamics (ANGO) Stock Forecast & Price Target

AngioDynamics (ANGO) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AngioDynamics Inc. is experiencing positive momentum through the growing adoption of its Auryon platform in both outpatient-based and hospital settings, which is enhancing the average selling price (ASP) of its offerings. The company is projected to improve its gross margins to 52.5% as it accelerates its manufacturing initiatives and benefits from a favorable revenue mix shift towards higher-margin Med-Tech products. Additionally, management's confidence in continued growth is supported by an expanding customer base, increasing utilization rates in existing accounts, and successful pricing strategies.

Bears say

AngioDynamics Inc faces significant financial challenges, including anticipated tariff headwinds estimated at $4 million to $6 million, which could dampen profit margins. Furthermore, management has signaled concerns regarding inventory pressures in the second half of fiscal 2026 due to rising raw material costs, potentially straining operational efficiency. Although recent capital sales suggest a possible positive trend in disposable demand, the concerning inventory and cost pressures raise doubts about the company's ability to sustain growth moving forward.

AngioDynamics (ANGO) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AngioDynamics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AngioDynamics (ANGO) Forecast

Analysts have given AngioDynamics (ANGO) a Strong Buy based on their latest research and market trends.

According to 3 analysts, AngioDynamics (ANGO) has a Strong Buy consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AngioDynamics (ANGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.